Dr. Matthew Abramowitz, MD
Claim this profileUniversity of Miami
Studies Prostate Cancer
Studies Stomach Cancer
8 reported clinical trials
19 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
Stage II
Stage I
2Stomach Cancer
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Matthew Abramowitz, MD is currently running
Sotagliflozin
for Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D. One of the few T1D studies conducted to date showed that implementing an enhanced DKA prevention plan can reduce the risk of DKA associated with the SGLT2i sotagliflozin (SOTA) to very low levels. In the present study, a similar DKA prevention program will be used to carry-out a 3-year trial to test the kidney benefit of SOTA in 150 persons with T1D and moderate to advanced DKD. After a 2-month period, during which diabetes care will be standardized and education on monitoring and minimizing DKA implemented, eligible study subjects will be randomly assigned (50/50) to take one tablet of SOTA (200 mg) or a similarly looking inactive tablet (placebo) every day for 3 years followed by 2-months without treatment. Neither the participants nor the study staff will know whether a person was assigned to taking SOTA or the inactive tablet. Kidney function at the end of the study will be compared between the two treatment groups to see whether SOTA prevented kidney function loss in those treated with this drug as compared to those who took the inactive tablet. The DKA prevention program will include participant education, close follow-up with study staff, continuous glucose monitoring, and systematic ketone body self-monitoring with a meter provided by the study. If successful, this study will provide efficacy and safety data that could be used to seek FDA approval of SOTA for the prevention of kidney function decline in patients with T1D and DKD.
Recruiting1 award Phase 3
DaRT Seeds
for Skin Cancer
This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy, as well as to assess the Duration of Response (DOR) 6 months from initial response. Secondary objectives are to assess the safety of DaRT, and to assess the progression free survival (PFS), overall survival (OS), Overall Duration of Response (O-DOR), local control and quality of life (QOL) for patients treated with DaRT.
Recruiting1 award N/A24 criteria
More about Matthew Abramowitz, MD
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Matthew Abramowitz, MD has experience with
- Mapped Tumor Salvage RT (MTSRT)
- Standard Salvage Radiation Treatment (SSRT)
- Accelerated Hypofractionation Radiotherapy
- Extended Hypofractionation Radiotherapy
- 177Lu-PSMA-617
- 68Ga-PSMA-11
Breakdown of trials Matthew Abramowitz, MD has run
Prostate Cancer
Stomach Cancer
Prostate Adenocarcinoma
Diabetic Kidney Disease
Chronic Kidney Failure
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Abramowitz, MD specialize in?
Matthew Abramowitz, MD focuses on Prostate Cancer and Stomach Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are Stage II.
Is Matthew Abramowitz, MD currently recruiting for clinical trials?
Yes, Matthew Abramowitz, MD is currently recruiting for 3 clinical trials in Miami Florida. If you're interested in participating, you should apply.
Are there any treatments that Matthew Abramowitz, MD has studied deeply?
Yes, Matthew Abramowitz, MD has studied treatments such as Mapped Tumor Salvage RT (MTSRT), Standard Salvage Radiation Treatment (SSRT), Accelerated Hypofractionation Radiotherapy.
What is the best way to schedule an appointment with Matthew Abramowitz, MD?
Apply for one of the trials that Matthew Abramowitz, MD is conducting.
What is the office address of Matthew Abramowitz, MD?
The office of Matthew Abramowitz, MD is located at: University of Miami, Miami, Florida 33136 United States. This is the address for their practice at the University of Miami.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.